Clinical Prophylaxis
Dr. Carcao is a Haematologist in the Division of Haematology/Oncology, and Professor of Paediatrics at the University of Toronto. He is Director of the Haemophilia and Bleeding disorders’ program at the Hospital for Sick Children.
Dr. Carcao received his medical degree in 1990 and a Master of Science degree in Clinical Epidemiology in 2007 from the University of Toronto. He joined the division of Haematology/Oncology as a faculty member in 1999.
Dr Carcao was President of the Association of Hemophilia Clinic Directors of Canada (2006-08) and Chair of the Canadian Paediatric Thrombosis & Haemostasis Network (2016-18). He is the author of over 200 peer-reviewed papers and textbook chapters. He is a prolific speaker giving talks throughout the world including plenary sessions at WFH, ISTH and other international meetings.
His research interests include congenital bleeding disorders, genetics, prophylaxis needs, pharmacokinetics, and inhibitor development; childhood immune thrombocytopenia; hereditary spherocytosis and more recently in the medical management of vascular malformations.
In 2023 he was awarded the Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research – a 5-10 year chair whose goal is to develop a Vascular Anomalies program and center.
1. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-684.
2. Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. J Thromb Haemost. 2019;17(7):1085-1096.
3. Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143-148.
4. Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results [published correction appears in Blood. 2023 Mar 23;141(12):1495]. Blood. 2022;139(26):3699-3707.